|Friday, 16 December 2011 08:38|
The passage of this Act reauthorizes and purchase propecia online without prescription amends the SBIR/STTR programs, which help fund small innovative companies on the brink of new technologies and cialis canadian cost discoveries.
BIO President and cheap viagra from canada CEO Jim Greenwood issued the following statement today:
“BIO and our members have long advocated for the reauthorization of, and changes to, SBIR/STTR, which are critical sources of funding for emerging biotechnology companies in the early development stages of medical research for serious and life threatening diseases, including cancer, diabetes, HIV/AIDS, and Parkinson’s.
“We especially are pleased that this Act will allow majority venture capital-backed companies to once again compete for SBIR/STTR funds, which will help level the playing field for small biotechnology companies so that they can continue to bring innovative medical treatments and soft viagra cures to market. Allowing companies that are primarily funded through venture capital to compete once again for SBIR/STTR grants will increase the number of new medical discoveries and cialis buy overnight innovations available to patients.
“Drug development can take up to $1 billion and healthcare canadian pharmacy 10 years and brand viagra at the very earliest stages, multiple sources of financing including SBIR/STTR grants have been instrumental in advancing research and propecia online pharmacy development in biotechnology.
“Biotechnology is a capital-intensive industry and original brand cialis securing funding has never been more critical or more challenging than it is right now.
“In recent months, many U.S. public biotechnology companies have been forced to placed drug development programs on hold or cut programs all together due to lack of capital. These programs include promising therapies for HIV/AIDS, cervical cancer, and diabetes, among other diseases.
“The seed money secured today from programs such as SBIR/STTR has the potential to yield the cutting-edge, life-saving therapies and buy viagra no prescription online cures of tomorrow. BIO applauds the Congress for recognizing the importance of these programs and cialis usa paving the way for future medical advancements and viagra rx breakthroughs that will ultimately benefit individual patients and the public health at large."
For additional data and analysis on the U.S. biotechnology industry, please visit www.bio.org.
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtech Now, an online portal and monthly newsletter chronicling “innovations transforming our world.” Subscribe to BIOtech Now.
For more information:
Upcoming BIO Events
BIO Asia International Partnering Conference
BIO CEO & Investor Conference
World Congress on Industrial Biotechnology & Bioprocessing
2012 BIO International Convention